Evolus licenses Profhilo for U.S. skin-quality market; no upfront payment

Evolus, Inc.

Exclusive license to develop and commercialize Profhilo in the U.S. for aesthetics and dermatology.
No upfront or milestone payments; economics via transfer-price model supporting target gross margins.
Evolus responsible for U.S. development and FDA approval; initial term 15 years from first approval.
Profhilo has 4.8M+ treatments globally since 2015; market leader in European injectable skin quality.
Agreement does not affect 2026 revenue/opex/operating profit outlook or 2028 targets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.